Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.54 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.54 |
| ▸ | NAMPT | P43490 | 11/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | MMP13 | P45452 | 1/20 | 0.50 |
| ▸ | PRKCA | P17252 | 1/20 | 0.50 |
| ▸ | GRK2 | P25098 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1475058 | 0.87 | RAB9A (0.71) | NAMPTRAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL1476776 | 0.83 | RAB9A (0.59) | HTTNAMPTRAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL1474947 | 0.83 | ALDH1A1 (0.57) | HTTRAB9AKMT2ASMN1; SMN2EPHX2 | |
| SCHEMBL1475683 | 0.82 | RAB9A (0.70) | HTTRAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL1474978 | 0.78 | ALDH1A1 (0.70) | HTTRAB9AKMT2ASMN1; SMN2EPHX2 | |
| SCHEMBL6391428 | 0.76 | ALDH1A1 (0.54) | RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL11616834 | 0.75 | HTT (1.00) | HTTROCK2ROCK1NAMPTRAB9A | |
| SCHEMBL15196632 | 0.75 | OTUD7B (0.42) | RAB9AKMT2ASMN1; SMN2EPHX2 | |
| SCHEMBL1474935 | 0.72 | FAAH (0.81) | HTTRAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL1474889 | 0.72 | RAB9A (0.73) | ROCK2ROCK1RAB9AKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1971600-B1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK BIOPHARMACEUTICALS CO LTD (KR) | 2013-08-21 | — | — | EP | claimed |
| US-20090131336-A1 | Isoxazole Derivatives and Use Thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2009-05-21 | — | — | US | claimed |
| EP-1971600-A1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK Holdings Co., Ltd. (KR) | 2008-09-24 | — | — | EP | claimed |
| WO-2007078113-A1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK HOLDINGS CO., LTD. (KR) | 2007-07-12 | — | — | WO | claimed |
| EP-1971600-B1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK BIOPHARMACEUTICALS CO LTD (KR) | 2013-08-21 | — | — | EP | disclosed |
| EP-1971600-B1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK BIOPHARMACEUTICALS CO LTD (KR) | 2013-08-21 | — | — | EP | disclosed |
| US-7915297-B2 | Isoxazole derivatives and use thereof | SK HOLDINGS CO., LTD. (KR) | 2011-03-29 | — | — | US | disclosed |
| US-7915297-B2 | Isoxazole derivatives and use thereof | SK HOLDINGS CO., LTD. (KR) | 2011-03-29 | — | — | US | disclosed |
| US-7915297-B2 | Isoxazole derivatives and use thereof | SK HOLDINGS CO., LTD. (KR) | 2011-03-29 | — | — | US | disclosed |
| US-20090131336-A1 | Isoxazole Derivatives and Use Thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2009-05-21 | — | — | US | disclosed |
| US-20090131336-A1 | Isoxazole Derivatives and Use Thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2009-05-21 | — | — | US | disclosed |
| US-20090131336-A1 | Isoxazole Derivatives and Use Thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2009-05-21 | — | — | US | disclosed |
| EP-1971600-A1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK Holdings Co., Ltd. (KR) | 2008-09-24 | — | — | EP | disclosed |
| WO-2007078113-A1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK HOLDINGS CO., LTD. (KR) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131336-A1 | Isoxazole Derivatives and Use Thereof | WNT3A, WNT1, WNT3 | HTT 4168/4885ROCK2 2181/4885ROCK1 2440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.